Accessing Hepatitis C patients who are difficult to reach: It is time to overcome barriers

Journal of Viral Hepatitis

Volumn 19, Issue 12, 2012, Pages 829-835

  Bruggmann, P ^a  

^a Arud Centres of Addiction Medicine   (Switzerland)

Author keywords

barriers; drug user; hepatitis C virus; injecting drug use; people who inject drugs; treatment uptake

Indexed keywords

ANTIVIRUS AGENT;

COGNITIVE THERAPY; DOCTOR PATIENT RELATION; DRUG DEPENDENCE; HEALTH CARE ACCESS; HEALTH INSURANCE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; MENTAL HEALTH CARE; MORBIDITY; MORTALITY; MOTIVATION; NONHUMAN; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; REINFECTION; REVIEW; SOCIAL SUPPORT;

ANTIVIRAL AGENTS; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES ADMINISTRATION; HEPATITIS C; HUMANS;

EID: 84868596510     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12008     Document Type: Review

References (83)

1. Chung RT,. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366 (3): 273-275.
2. Clark PJ, Muir AJ,. Overcoming barriers to care for hepatitis C. N Engl J Med 2012; 366 (26): 2436-2438.
3. Nelson PK, Mathers BM, Cowie B, et al,. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378 (9791): 571-583.
4. Weber R, Sabin CA, Friis-Moller N, et al,. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166 (15): 1632-1641.
5. Grebely J, Dore GJ,. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31 (4): 331-339.
6. Grebely J, Raffa JD, Lai C, et al,. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat 2011; 18 (1): 32-41.
7. Matser A, Urbanus A, Geskus R, et al,. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107 (3): 614-623.
8. Hutchinson SJ, Bird SM, Goldberg DJ,. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42 (3): 711-723.
9. Zeiler I, Langlands T, Murray JM, Ritter A,. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 2010; 110 (3): 228-233.
10. Vickerman P, Martin N, Hickman M,. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere Drug Alcohol Depend 2011; 113 (2-3): 83-85.
11. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M,. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility J Hepatol 2011; 54 (6): 1137-1144.
12. Lettmeier B, Muhlberger N, Schwarzer R, et al,. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49 (4): 528-536.
13. Mehta SH, Genberg BL, Astemborski J, et al,. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33 (3): 126-133.
14. Grebely J, Petoumenos K, Matthews GV, et al,. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend 2010; 107 (2-3): 244-249.
15. Grebely J, Raffa JD, Lai C, et al,. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16 (5): 352-358.
16. Strathdee SA, Latka M, Campbell J, et al,. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40 (Suppl. 5): S304-S312.
17. Lindenburg CE, Lambers FA, Urbanus AT, et al,. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23 (1): 23-31.
18. Volk ML, Tocco R, Saini S, Lok AS,. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50 (6): 1750-1755.
19. Grebely J, Bryant J, Hull P, et al,. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011; 18 (4): e104-e116.
20. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144 (10): 705-714.
21. Hagan H, Campbell J, Thiede H, et al,. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006; 121 (6): 710-719.
22. Kwiatkowski CF, Fortuin CK, Booth RE,. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002; 97 (10): 1289-1294.
23. Schulthess K,. Versorgungsqualität von opioidsubstituierten Patienten mit chronischer Hepatitis C-Eine Querschnitt-Studie im Kanton Zürich University of Zurich, Switzerland; 2011.
24. Strehlow AJ, Robertson MJ, Zerger S, et al,. Hepatitis C among clients of health care for the homeless primary care clinics. J Health Care Poor Underserved 2012; 23 (2): 811-833.
25. Swan D, Long J, Carr O, et al,. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010; 24 (12): 753-762.
26. Shehab TM, Sonnad SS, Lok AS,. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8 (5): 377-383.
27. Shehab TM, Orrego M, Chunduri R, Lok AS,. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003; 98 (3): 639-644.
28. Rein DB, Smith BD, Wittenborn JS, et al,. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156 (4): 263-270.
29. Bini EJ, Kritz S, Brown LS Jr, Robinson J, Alderson D, Rotrosen J,. Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis 2011; 30 (2): 98-109.
30. Monnet E, Collin-Naudet E, Bresson-Hadni S, et al,. Place of residence and distance to medical care influence the diagnosis of hepatitis C: a population-based study. J Hepatol 2006; 44 (3): 499-506.
31. Shiffman ML, Mihas AA, Millwala F, et al,. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007; 102 (4): 761-766.
32. Rocca LG, Yawn BP, Wollan P, Kim WR,. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2004; 2 (2): 116-124.
33. Stoove MA, Gifford SM, Dore GJ,. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005; 77 (1): 81-86.
34. Overbeck K, Bruggmann P, Helbling B,. Chronic Hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment? Eur J Gen Pract 2011; 17 (2): 103-108.
35. Evon DM, Simpson KM, Esserman D, Verma A, Smith S, Fried MW,. Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. Aliment Pharmacol Ther 2010; 32 (9): 1163-1173.
36. Shiffman ML, Stewart CA, Hofmann CM, et al,. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000; 182 (6): 1595-1601.
37. Zeuzem S, Alberti A, Rosenberg W, et al,. Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. Aliment Pharmacol Ther 2006; 24 (8): 1133-1149.
38. Kanwal F, Hoang T, Spiegel BM, et al,. Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology 2007; 46 (6): 1741-1749.
39. Treloar C, Newland J, Rance J, Hopwood M,. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat 2010; 17 (12): 839-844.
40. Dore GJ, Hellard M, Matthews GV, et al,. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138 (1): 123-135.
41. Hellard M, Sacks-Davis R, Gold J,. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49 (4): 561-573.
42. Zanini B, Lanzini A,. Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review. Antivir Ther 2009; 14 (4): 467-479.
43. Doab A, Treloar C, Dore GJ,. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40 (Suppl. 5): S313-S320.
44. Walley AY, White MC, Kushel MB, Song YS, Tulsky JP,. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005; 28 (2): 181-187.
45. Grebely J, Genoway KA, Raffa JD, et al,. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93 (1-2): 141-147.
46. Zickmund SL, Campbell SA, Tirado CF, Zook CL, Weinrieb RM,. Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment. J Addict Med 2012; 6 (3): 233-239.
47. Savant JD, Barry DT, Cutter CJ, et al,. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug Alcohol Depend 2012; http://www. sciencedirect.com/science/article/pii/S0376871612002529.
48. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W,. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9 (6): 847-854.
49. Golden J, O'Dwyer AM, Conroy RM,. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27 (6): 431-438.
50. Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR,. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS 2005; 19 (Suppl. 3): S208-S214.
51. Litwin AH, Kunins HV, Berg KM, et al,. Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat 2007; 33 (1): 99-105.
52. Grebely J, Tyndall MW,. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS 2011; 6 (6): 501-507.
53. Myles A, Mugford GJ, Zhao J, Krahn M, Wang PP,. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol 2011; 25 (3): 135-139.
54. Paterson BL, Backmund M, Hirsch G, Yim C,. The depiction of stigmatization in research about hepatitis C. Int J Drug Policy 2007; 18 (5): 364-373.
55. Moore GA, Hawley DA, Bradley P,. Hepatitis C: studying stigma. Gastroenterol Nurs 2008; 31 (5): 346-352.
56. Reimer J, Haasen C,. Need-adapted HCV-treatment setting for injection drug users. Lancet 2009; 373 (9681): 2090-2091.
57. Stepanova M, Kanwal F, el-Serag HB, Younossi ZM,. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53 (3): 737-745.
58. Thomas DL, Leoutsakas D, Zabransky T, Kumar MS,. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc 2011; 14: 22.
59. Litwin AH, Smith BD, Drainoni ML, et al,. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis 2012; 44 (6): 497-503.
60. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB,. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011; 43 (1): 66-72.
61. Knott A, Dieperink E, Willenbring ML, et al,. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101 (10): 2254-2262.
62. Sylvestre DL, Clements BJ,. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19 (9): 741-747.
63. Grebely J, Knight E, Genoway KA, et al,. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22 (3): 270-277.
64. Treloar C, Hull P, Dore GJ, Grebely J,. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev 2012; doi: 10.1111/j.1465-3362.2012.00468.x.
65. Bruggmann P, Falcato L, Dober S, et al,. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008; 15 (10): 747-752.
66. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G,. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40 (1): 120-124.
67. Robaeys G, Van VH, Mathei C, Van RM, Bruckers L, Buntinx F,. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006; 18 (2): 159-166.
68. Schaefer M, Capuron L, Friebe A, et al,. Hepatitis C infection, antiviral treatment and Mental Health: A European Expert Consensus Statement. J Hepatol 2012; doi: 10.1016/j.jhep.2012.07.037.
69. Corson S, Greenhalgh D, Palmateer N, Weir A, Hutchinson S,. Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. Int J Drug Policy 2011; 22 (2): 102-108.
70. Foucher J, Reiller B, Jullien V, et al,. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. J Viral Hepat 2009; 16 (2): 121-131.
71. Moessner BK, Jorgensen TR, Skamling M, et al,. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 2011; 106 (5): 970-976.
72. Arora S, Thornton K, Murata G, et al,. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364 (23): 2199-2207.
73. Wilkinson M, Crawford V, Tippet A, et al,. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment Pharmacol Ther 2009; 29 (1): 29-37.
74. Jack K, Willott S, Manners J, Varnam MA, Thomson BJ,. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 2009; 29 (1): 38-45.
75. Litwin AH, Harris KA Jr, Nahvi S, et al,. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37 (1): 32-40.
76. Belfiori B, Ciliegi P, Chiodera A, et al,. Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Dig Liver Dis 2009; 41 (4): 303-307.
77. Harris KA Jr, Arnsten JH, Litwin AH,. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4 (1): 20-26.
78. Evon DM, Simpson K, Kixmiller S, et al,. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol 2011; 106 (10): 1777-1786.
79. Hill WD, Butt G, Alvarez M, Krajden M,. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol 2008; 22 (1): 27-32.
80. Boonwaat L, Haber PS, Levy MH, Lloyd AR,. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust 2010; 192 (9): 496-500.
81. Farley JD, Wong VK, Chung HV, et al,. Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol 2005; 19 (3): 153-156.
82. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD,. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138 (3): 187-190.
83. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM,. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003; 52 (10): 1500-1504.